Evaluating 68Ga-Pentixafor PETCT Compared to 18F-FDG PETCT for Staging Hematological Cancers

What this Trial Is About

Researchers are evaluating the use of 68Ga-pentixafor PET imaging alongside 18F-FDG PET imaging for patients with hematological malignancies such as non-Hodgkins lymphoma and myeloma. This prospective, open-label study involves 120 patients confirmed by pathology to have these cancers. The goal is to see if 68Ga-pentixafor PET can be a reliable complement to the standard 18F-FDG PET for clinical staging, assessing treatment response, and re-staging. Participants will undergo both 18F-FDG PETCT and 68Ga-pentixafor PETCT scans within 7 days after enrollment. Before scans, medical history and lab tests are collected. Pathological results from biopsy or surgery within one month after imaging serve as the diagnostic reference. A follow-up period of six months monitors patients. The imaging agents are prepared under strict quality standards and administered intravenously at specified doses. During the study, researchers collect imaging data, medical history, and lab results, then compare PETCT findings to pathology outcomes. They measure uptake values like SUVmax and SUVmean of the tracers one day after injection. The study also involves safety monitoring through follow-up visits over six months. Participation duration includes screening, imaging, biopsy, and follow-up until December 2025.

A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging